β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trialsXavier Rosselló, John Munkhaugen, Pedro L. Sánchez et al.|The Lancet|2025Cited by 63
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point studyJohn Munkhaugen, Dan Atar, Vidar Ruddox et al.|American Heart Journal|2018Cited by 50
Beta-Blockers after Myocardial Infarction with Normal Ejection FractionAnna Meta Dyrvig Kristensen, Borja Ibáñez, Xavier Rosselló et al.|New England Journal of Medicine|2025Cited by 39
Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trialOscar Kristiansen, John Munkhaugen, Nils Tore Vethe et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2020Cited by 25
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristicsAnna Meta Dyrvig Kristensen, Dan Atar, John Munkhaugen et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2023Cited by 21